Q1 Earnings Estimate for ALLO Issued By Zacks Research

Allogene Therapeutics, Inc. (NASDAQ:ALLO) – Analysts at Zacks Research issued their Q1 2027 EPS estimates for Allogene Therapeutics in a research report issued on Wednesday, April 2nd. Zacks Research analyst R. Department forecasts that the company will earn ($0.32) per share for the quarter. The consensus estimate for Allogene Therapeutics’ current full-year earnings is ($1.28) per share. Zacks Research also issued estimates for Allogene Therapeutics’ FY2027 earnings at ($1.18) EPS.

ALLO has been the subject of several other research reports. HC Wainwright cut their target price on Allogene Therapeutics from $9.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday, March 19th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $10.00 price objective on shares of Allogene Therapeutics in a research note on Friday, March 14th. Citizens Jmp upgraded shares of Allogene Therapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 target price on the stock in a research report on Friday, March 14th. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $14.00 price target on shares of Allogene Therapeutics in a research note on Friday, March 14th. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $9.29.

Allogene Therapeutics Stock Up 4.3 %

ALLO opened at $1.44 on Friday. The business’s fifty day simple moving average is $1.81 and its 200 day simple moving average is $2.20. Allogene Therapeutics has a 52 week low of $1.30 and a 52 week high of $4.25. The stock has a market cap of $312.86 million, a PE ratio of -0.92 and a beta of 0.99.

Allogene Therapeutics (NASDAQ:ALLO) last released its quarterly earnings results on Thursday, March 13th. The company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.06.

Insider Activity

In other news, CEO David D. Chang sold 46,668 shares of Allogene Therapeutics stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $1.96, for a total transaction of $91,469.28. Following the sale, the chief executive officer now owns 5,276,569 shares of the company’s stock, valued at approximately $10,342,075.24. The trade was a 0.88 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Timothy L. Moore sold 14,746 shares of the business’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $1.71, for a total transaction of $25,215.66. Following the transaction, the insider now owns 250,713 shares in the company, valued at $428,719.23. This represents a 5.55 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 104,866 shares of company stock valued at $194,461. Company insiders own 24.30% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in ALLO. Lynx1 Capital Management LP increased its stake in shares of Allogene Therapeutics by 75.3% in the 4th quarter. Lynx1 Capital Management LP now owns 10,874,723 shares of the company’s stock worth $23,163,000 after acquiring an additional 4,672,349 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in Allogene Therapeutics by 30.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 3,561,626 shares of the company’s stock worth $7,586,000 after purchasing an additional 831,146 shares during the period. Foresite Capital Management VI LLC bought a new position in shares of Allogene Therapeutics during the fourth quarter valued at approximately $7,345,000. Geode Capital Management LLC lifted its holdings in shares of Allogene Therapeutics by 14.4% during the third quarter. Geode Capital Management LLC now owns 3,227,104 shares of the company’s stock valued at $9,037,000 after purchasing an additional 407,070 shares during the last quarter. Finally, Two Sigma Advisers LP boosted its position in shares of Allogene Therapeutics by 12.1% in the 4th quarter. Two Sigma Advisers LP now owns 2,702,200 shares of the company’s stock worth $5,756,000 after purchasing an additional 291,800 shares in the last quarter. Institutional investors own 83.63% of the company’s stock.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).